A new wrestler in the battle between alpha- and beta-secretases for cleavage of APP.
Modulation of the proteases that process the amyloid precursor protein (APP) is a major therapeutic strategy for the treatment and prevention of Alzheimer's disease (AD). The discovery of a novel endogenous modulator of alpha-secretase-mediated, in preference to beta-secretase-mediated, cleavage of APP implicates sumoylation in the etiology of AD, and offers a new therapeutic target for intervention in APP processing.
Neve
Rachael L
RL
Department of Psychiatry, Harvard Medical School, MRC 223, McLean Hospital, 115 Mill Street, Belmont, MA 02478, USA. neve@helix.mgh.harvard.edu
D000544:Alzheimer Disease / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases; D016564:Amyloid beta-Protein Precursor / Q000378:metabolism*; D000818:Animals; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism*; D010450:Endopeptidases / Q000378:metabolism*; D015398:Signal Transduction; D014452:Ubiquitins / Q000378:metabolism*
D016564:Amyloid beta-Protein Precursor; D014452:Ubiquitins; D053829:Amyloid Precursor Protein Secretases; D010450:Endopeptidases; D016282:Aspartic Acid Endopeptidases